SK Biopharmaceuticals has signed a licensing agreement with Eurofarma, a Brazilian pharmaceutical company, to develop and commercialise cenobamate in Latin America for epilepsy treatment.
SwanBio Therapeutics, a gene therapy company, has raised $56m through Series B financing round to advance gene therapies for neurological conditions.
Apnimed has raised $62.5m funding in a Series C round led by new investor Sectoral Asset Management to advance new pharmaceutical treatments development for obstructive sleep apnea (OSA) and related sleep disorders.
The US Food and Drug Administration (FDA) has approved an expanded indication for Supernus Pharmaceuticals’ Qelbree (viloxazine extended-release capsules) to treat attention deficit hyperactivity disorder (ADHD) in adult patients of the age 18 and above.
Pfizer and Biohaven Pharmaceutical have announced receipt of marketing authorisation from the European Commission (EC) for Vydura (rimegepant).
AbbVie has submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for its therapy cariprazine (VRAYLAR) to treat major depressive disorder (MDD).
Neurimmune and Ono Pharmaceutical have announced the expansion of a drug discovery partnership agreement to develop antibody drugs for neurodegenerative diseases.
Pfizer and Beam Therapeutics have entered into an exclusive four-year research collaboration focused on in vivo base editing programmes for three targets for rare genetic diseases of liver, central nervous system, liver and muscle.
Biotechnology firm AgeX Therapeutics has announced a research collaboration with the University of California, Irvine (UCI) on research programme for exosome-based treatments for some brain disorders.
Recursion, a clinical-stage biotechnology company, has announced a collaboration with Roche and Genentech, a member of the Roche Group.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.